BioMind has launched an artificial intelligence (AI) application to assist in the detection of COVID-19 associated pneumonia on medical imaging. The AI application identifies anomalies in the lungs and assists in detection of COVID-19 pneumonia. It analyses the lung pathology on chest CT to aid in the assessment and comes with triage capability. With the sudden surge in admission of respiratory-related patients globally, triaging can help to reduce the increasing burden on the intensive care units (ICU) and address the shortage of medical resources. Raymond Moh, CEO of BioMind, said: "We are proud to receive the Health Sciences Authority's approval for our COVID-19 diagnostics support product. This was born out of the immense efforts and collaborations between clinicians, lung specialists and our engineers. In an unprecedented crisis like this, we hope to quickly scale our solution in Asia, Europe, Middle East and USA to equip physicians with smart tools to detect and manage COVID-19 pneumonia. Artificial intelligence will be their useful assistant daily in this long battle."

In response to the COVID-19 outbreak, AI company BioMind developed a solution (BioMind AI-COVID) with the aim of diagnosing COVID-19 Pneumonia in a fast, accurate and cost-effective manner. It has since been deployed in hospitals across China, and is intent on expanding its footprint globally. Ian Bolland found out more. Give us some background about BioMind – who developed it? BioMind is an award-winning Artificial Intelligence company that specialises in creating predictive applications to assist doctors in their daily work.

The BioMind AI system was developed by the Artificial Intelligence Research Centre for Neurological Disorders at the Beijing Tiantan Hospital and it has scored 2:0 against elite physicians in a brain diagnosing competition held in Beijing. The AI made correct diagnoses in 87% of 225 cases in roughly 15 minutes, whereas the team of human doctors only managed to achieve a 66% accuracy. BioMind was also successful in detecting brain hematoma expansion cases. In order for BioMind to be trained, the developers fed it thousands of images of nervous system diseases that were archived by the hospital in the past 10 years. Its success was not intended to pit the doctors against medical technology, on the contrary, it would be expected for the AI to work with the medical professionals and make those who were skeptical about it more accepting.

A custom-built AI designed to diagnose brain tumors and predict hematoma expansion dominated some of China's best doctors in a competition last Saturday in Beijing. The AI, dubbed BioMind, ultimately scored 2:0 against its human competitors, comprised of 15 senior doctors from China's premier hospitals. BioMind was developed by a collaboration between a team from the Artificial Intelligence Research Center for Neurological Disorders at the Beijing Tiantan Hospital and researchers from the Capital Medical University. BioMind's developers opted to feed the AI with data sets featuring tens of thousands of images depicting nervous-system-related diseases, which were retrieved from Tiantan Hospital's archives stretching over the past decade. Wang Yongjun, executive vice-president of Tiantan Hospital, stated that this training ultimately enabled the AI to become proficient in diagnosing neurological diseases such as meningioma and glioma with an accuracy rate of over 90%.

An artificial intelligence (AI) system scored 2:0 against elite human physicians in two rounds of competitions in diagnosing brain tumors and predicting hematoma expansion in Beijing. The BioMind AI system made correct diagnoses in 87 percent of 225 cases in about 15 minutes, while a team of 15 senior doctors only achieved 66-percent accuracy.

Biomind was developed in a joint venture between a Singaporean tech company, Hanalytics, and China's prestigious Tiantan Hospital. Since December, when the venture started up, tens of thousands of medical images collected over a decade have been used to teach Biomind its job. After months of deep learning, the machine was ready for a competition against 25 experienced doctors at Beijing's China National Convention Center testing their ability to analyze images of the brain.

An AI system has wiped the floor with some of China's top doctors when it comes to diagnosing brain tumors and predicting hematoma expansion. As reported by Xinhua, the system defeated a team comprised of 15 of China's top doctors by a margin of two to one. The AI, BioMind, was developed by the Artificial Intelligence Research Centre for Neurological Disorders at Beijing Tiantan Hospital, and is another example of the long line of the technology analyzing images. When diagnosing brain tumors, BioMind was correct 87 percent of the time, compared to 66 percent by the medical professionals. The AI also only took 15 minutes to diagnose the 225 cases, while doctors took 30.

HOW many times have we heard of doctors misdiagnosing patient? It's why most people prefer to get a second and maybe even a third opinion about serious medical conditions. However, with advancements in artificial intelligence (AI), can you imagine how amazing it would be if we could build and train algorithms that look for all the right markers, consider several hundred factors, and take into account all the possible permutations and combinations to deliver "perfect" or even "near perfect" results? Well, news from China suggests that the technology just came to life. According to The Star, an AI-powered system, dubbed BioMind by its creators at the AI Research Centre for Neurological Disorders and Capital Medical University, has defeated elite physicians in two rounds of a medical competition in Beijing.

Biomind, an artificial intelligence (AI) machine, can read MRI scans and diagnose neurological conditions like tumours in a second, its maker, Hanalytics, has claimed. In contrast, a doctor will take an hour on average to study the images and draw up a report, the Singapore start-up said. But while AI machines like Bio-mind are increasingly outperforming humans, they can never totally replace them. This was a recurring theme at the inaugural Sino-Singapore Artificial Intelligence Forum yesterday. The reason has to do with the importance of the human touch.